PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.07%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is -0.07%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
822.03%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.11%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
-112.41%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 21.91%. Seth Klarman would check if external or internal factors caused the decline.
-112.41%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 19.58%. Seth Klarman would check if structural or cyclical issues are at play.
85.63%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 43.47%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
86.67%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 44.17%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
87.78%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 44.21%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
11.12%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
13.10%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-125.44%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is -13.21%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-88.64%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is -6.35%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
549.91%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 18.23%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-39.53%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 13.95%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-3850.87%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-216.02%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
25.36%
3Y OCF/share growth of 25.36% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-2957.33%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 6.58%. Seth Klarman might see a fundamental problem if peers maintain growth.
-213.57%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 10.39%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-299.18%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 16.62%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
7956.19%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 53.08% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
304.44%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 13.50%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
30.41%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 4.15%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.22%
AR growth of 3.22% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-0.36%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
2.62%
We expand assets while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-7.54%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -1.16%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
5.45%
Slightly rising debt while Drug Manufacturers - Specialty & Generic median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
207.41%
We slightly increase R&D while Drug Manufacturers - Specialty & Generic is cutting. Peter Lynch sees a chance to grab market share with new offerings if ROI is managed well.
-7.22%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.